Compare IBEX & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBEX | AVIR |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.7M | 450.9M |
| IPO Year | 2017 | 2020 |
| Metric | IBEX | AVIR |
|---|---|---|
| Price | $27.24 | $5.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $35.00 | $8.00 |
| AVG Volume (30 Days) | 95.9K | ★ 576.4K |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.26 | 3.00 |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $558,273,000.00 | $351,367,000.00 |
| Revenue This Year | $13.14 | N/A |
| Revenue Next Year | $5.67 | N/A |
| P/E Ratio | $16.95 | ★ N/A |
| Revenue Growth | ★ 9.77 | N/A |
| 52 Week Low | $21.64 | $2.46 |
| 52 Week High | $42.99 | $6.45 |
| Indicator | IBEX | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 32.24 | 47.24 |
| Support Level | N/A | $3.33 |
| Resistance Level | $30.14 | $6.45 |
| Average True Range (ATR) | 0.92 | 0.37 |
| MACD | 0.09 | -0.11 |
| Stochastic Oscillator | 3.39 | 25.30 |
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.